# DNA Origami-Constructed Nanotapes for Sunitinib Adsorption and Inhibition of Renal Clear Carcinoma Cells

## TL;DR

Researchers created DNA-based nanotapes to deliver the cancer drug sunitinib more effectively to kidney cancer cells, improving its ability to block cancer-related proteins.

## Contribution

A novel DNA origami-based nanotape platform for efficient sunitinib delivery and RTK inhibition in renal carcinoma cells.

## Key findings

- DNA nanotapes with chitosan coating enable strong sunitinib adhesion via electrostatic interactions.
- The nanotapes show excellent serum stability and prolonged cell membrane retention.
- Sunitinib-loaded nanotapes significantly enhance cytotoxicity against 786-0 renal carcinoma cells.

## Abstract

Sunitinib (SUN) is a first-line drug for the treatment
of renal
clear carcinoma cells by targeting receptor tyrosine kinases (RTK)
on the cell membrane. However, the effective delivery of SUN to the
cell membrane remains a significant challenge. In this study, we fabricated
precisely structured DNA nanotapes with strong surface SUN adhesion,
enabling RTK inhibition of renal clear carcinoma cells. In our design,
the precisely assembled linear topological six-helical-bundle DNA
origami serves as the framework, and positively charged chitosan is
adsorbed onto the DNA origami surface, thereby forming DNA nanotapes.
The SUN was efficiently loaded onto the surface of the DNA nanotapes
by electrostatic interaction. We found that DNA nanotapes exhibit
excellent stability in serum. Importantly, DNA nanotapes carrying
SUN can achieve prolonged cell membrane retention and inhibit RTK,
thereby enhancing cytotoxicity toward 786-0 cells. Taken together,
this study provides a promising candidate platform for the efficient
delivery of cell membrane receptor inhibitors in anticancer therapy.